TG2/TGase Cancer Research Results

TG2/TGase, Transglutaminase 2: Click to Expand ⟱

Source:

Type:

Transglutaminase 2 is usually abbreviated TG2, also called tissue transglutaminase or TGM2 for the gene. In cancer biology, TG2 is generally treated as a pro-cancer survival, EMT, invasion, metastasis, cancer stemness, and therapy-resistance factor, although its effect can be context-dependent by cancer type, subcellular location, and enzymatic vs non-enzymatic/scaffold function. Recent reviews emphasize TG2 as a major driver of EMT, metastasis, drug resistance, and cancer-cell survival signaling.

| Field             | Entry                                                                                                                                                                         |
| ----------------- | -------------------------------------------------------------------------------- |
| Target / pathway  | Transglutaminase 2                                                                                                                                                            |
| Abbrev.           | TG2                                                                                                                                                                       |
| Gene              | TGM2                                                                                                                                                                      |
| Cancer direction  | Usually upregulated / activated in aggressive, invasive, metastatic, 
                      and drug-resistant cancers                                                                           |
| Cancer effect     | Mostly pro-cancer                                                                                                                                                         |
| Best cancer label | EMT / metastasis / chemoresistance / cancer stemness / NF-κB survival signaling                                                                                               |
| Therapeutic logic | TG2 inhibition or knockdown is usually expected to reduce invasion, EMT,
                     survival, stem-like traits, and drug resistance                                                  |
| Caution           | TG2 is multifunctional and can have context-specific effects; extracellular TG2,
                     intracellular TG2, catalytic activity, GTP-binding/scaffold activity, 
                     and cancer type matter |

HD, Huntington’s disease: Click to Expand ⟱

Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain. It affects movement, cognition, and behavior.

Scientific Papers found: Click to Expand⟱

4331-

Cyste,

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

in-vivo,

HD,

mice

NA,

AD,

*BDNF↑, *neuroP↑, *TG2/TGase↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Migration ⓘ

TG2/TGase↓, 1,

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,

Functional Outcomes ⓘ

neuroP↑, 1,
Total Targets: 3

Scientific Paper Hit Count for: TG2/TGase, Transglutaminase 2

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells